印度计划垄断市场,中国药企加速研发!“减肥神药”专利将过期,谁的机遇?

华尔街见闻
12 Apr 2024

印度《经济时报》近日报道称,随着丹麦制药巨头诺和诺德和美国医药公司礼来等减肥药专利即将到期,以印度药企Biocon为首的印度仿制药公司,瞄准1000亿美元的减肥药市场,并计划垄断该市场。但接受《环球时报》记者采访的业内人士表示,畅销减肥药物的专利即将到期,面对如此大的市场空间,印度想要垄断是不可能的。 印度药企Biocon瞄准千亿美元减肥药市场。图为Biocon工作人员在制药车间,图源:印媒 “...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10